https://www.nasdaq.com/press-release/abiomed-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2021-12-29
https://www.nasdaq.com/press-release/abiomed-to-present-at-upcoming-investor-conferences-2021-11-18
https://www.nasdaq.com/press-release/two-large-studies-demonstrate-complete-revascularization-with-impella-heart-pumps
https://www.nasdaq.com/press-release/impella-advances-to-higher-level-of-recommendation-in-newest-esc-guidelines-2021-11
https://www.nasdaq.com/press-release/tct-2021-to-highlight-improved-patient-outcomes-with-impellas-small-smart-and
https://www.nasdaq.com/press-release/abiomed-announces-q2-fy-2022-revenue-of-%24248-million-up-18-year-over-year-2021-10-28
https://www.nasdaq.com/press-release/abiomed-second-quarter-fiscal-2022-earnings-and-conference-call-notification-2021-10
https://www.nasdaq.com/press-release/abiomed-announces-record-revenue-of-%24253-million-up-53-year-over-year-2021-08-04
https://www.nasdaq.com/press-release/abiomed-first-quarter-fiscal-2022-earnings-and-conference-call-notification-2021-07
https://www.nasdaq.com/press-release/fda-grants-highest-level-of-approval-to-the-next-generation-of-impella-rp-to-treat
https://www.nasdaq.com/press-release/abiomed-acquires-precardia-a-breakthrough-medical-device-company-to-improve-outcomes
https://www.nasdaq.com/press-release/abiomed-to-present-at-upcoming-investor-conferences-2021-05-25
https://www.nasdaq.com/press-release/abiomed-announces-record-revenue-of-%24241-million-up-17-year-over-year-with-26.0
https://www.nasdaq.com/press-release/final-results-from-the-national-cardiogenic-shock-initiative-ncsi-study-demonstrate
https://www.nasdaq.com/press-release/dr.-paula-a.-johnson-joins-abiomed-board-of-directors-2021-04-28
https://www.nasdaq.com/press-release/first-patient-enrolled-in-protect-iv-randomized-controlled-trial-of-impella-2021-04
https://www.nasdaq.com/press-release/abiomed-fourth-quarter-fiscal-2021-earnings-and-conference-call-notification-2021-04
https://www.nasdaq.com/press-release/medcert-enables-the-use-of-the-single-access-procedure-with-impella-cp-introducer
https://www.nasdaq.com/press-release/abiomed-announces-appointment-of-dr.-myron-rolle-to-board-of-directors-2021-02-17
https://www.nasdaq.com/press-release/abiomed-to-present-at-upcoming-investor-conferences-2021-02-17
https://www.nasdaq.com/press-release/large-clinical-study-presented-at-sts-2021-finds-79-survival-rate-with-impella-5.5
https://www.nasdaq.com/press-release/abiomed-announces-q3-fy-2021-record-revenue-of-%24232-million-up-5-year-over-year-with
https://www.nasdaq.com/press-release/abiomed-third-quarter-fiscal-2021-earnings-and-conference-call-notification-2021-01
https://www.nasdaq.com/press-release/abiomed-continues-to-strengthen-its-intellectual-property-now-holds-more-than-1000
https://www.nasdaq.com/press-release/abiomed-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2020-12-29
https://www.nasdaq.com/press-release/first-patients-including-a-covid-19-patient-treated-with-abiomeds-innovative-ecmo
https://www.nasdaq.com/press-release/two-milestones-achieved-toward-small-bore-access-with-impella-2020-12-15
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-the-piper-sandler-32nd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-the-stephens-annual-investment-conference-2020-2020
https://www.nasdaq.com/press-release/first-1000-patients-treated-with-impella-5.5-with-smartassist-a-heart-pump-designed
https://www.nasdaq.com/press-release/abiomed-announces-q2-fy-2021-revenue-of-%24210-million-up-27-over-q1-fy-2021-and-up-2
https://www.nasdaq.com/press-release/first-patients-treated-with-the-worlds-smallest-heart-pump-the-9fr-impella-ecp-2020
https://www.nasdaq.com/press-release/fda-grants-510k-clearance-for-abiomeds-innovative-cardiopulmonary-support-technology
https://www.nasdaq.com/press-release/studies-presented-at-tct-connect-associate-higher-survival-with-early-identification
https://www.nasdaq.com/press-release/data-presented-at-tct-connect-finds-pre-pci-use-of-impella-for-ami-cardiogenic-shock
https://www.nasdaq.com/press-release/abiomed-to-host-a-virtual-meeting-to-discuss-new-clinical-data-presented-at-tct
https://www.nasdaq.com/press-release/largest-study-of-hemodynamically-supported-high-risk-pci-patients-finds-more-complete
https://www.nasdaq.com/press-release/restore-ef-study-demonstrates-impella-supported-high-risk-pci-improves-left
https://www.nasdaq.com/press-release/abiomed-second-quarter-fiscal-2021-earnings-and-conference-call-notification-2020-10
https://www.nasdaq.com/press-release/tct-connect-to-highlight-how-impella-enables-improved-outcomes-for-high-risk-pci
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-the-raymond-james-north-american-equities-conference
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-the-18th-annual-morgan-stanley-global-healthcare
https://www.nasdaq.com/press-release/abiomed-announces-q1-fy-2021-revenue-of-%24165-million-and-21-operating-margin-2020-08
https://www.nasdaq.com/press-release/fda-issues-emergency-use-authorization-for-impella-heart-pumps-to-provide-unloading
https://www.nasdaq.com/press-release/large-multi-center-study-in-japan-finds-high-survival-rates-with-use-of-impella-heart
https://www.nasdaq.com/press-release/abiomed-first-quarter-fiscal-2021-earnings-and-conference-call-notification-2020-07
https://www.nasdaq.com/press-release/fda-approves-data-streaming-from-the-impella-console-setting-the-stage-for-artificial
https://www.nasdaq.com/press-release/study-finds-84-survival-rate-in-patients-in-cardiogenic-shock-and-other-challenging
https://www.nasdaq.com/press-release/abiomed-launches-virtual-physician-education-program-camp-pci-to-improve-high-risk
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-the-william-blair-40th-annual-growth-stock
https://www.nasdaq.com/press-release/fda-issues-emergency-use-authorization-for-impella-rp-as-therapy-for-covid-19
https://www.nasdaq.com/press-release/abiomed-to-hold-fireside-chat-at-jefferies-virtual-healthcare-conference-2020-05-27
https://www.nasdaq.com/press-release/abiomed-to-host-virtual-clinical-data-and-innovation-day-2020-05-20
https://www.nasdaq.com/press-release/protect-iii-study-shows-placing-impella-prior-to-high-risk-pci-is-associated-with
https://www.nasdaq.com/press-release/abiomed-announces-q4-fy-2020-revenue-of-%24207-million-and-28.1-operating-margin-2020
https://www.nasdaq.com/press-release/abiomed-fourth-quarter-fiscal-2020-earnings-and-conference-call-notification-2020-04
https://www.nasdaq.com/press-release/study-of-21848-high-risk-pci-patients-demonstrates-lower-risk-of-death-and
https://www.nasdaq.com/press-release/abiomed-announces-q3-fy-2020-revenue-of-%24222-million-and-31.7-operating-margin-2020
https://www.nasdaq.com/press-release/abiomed-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference-2019-12-30
https://www.nasdaq.com/press-release/abiomed-abmd-alert%3a-johnson-fistel-launches-investigation-into-abiomed-inc.-investors
https://www.nasdaq.com/press-release/abiomed-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-2019-11-27
https://www.nasdaq.com/press-release/abiomed-medical-office-completes-review-of-observational-analysis-of-impella
https://www.nasdaq.com/press-release/clinical-review-demonstrates-cost-effectiveness-of-impella-in-high-risk-pci-and
https://www.nasdaq.com/press-release/first-u.s.-patients-treated-with-impella-5.5-with-smartassist-a-minimally-invasive
https://www.nasdaq.com/press-release/abiomed-announces-q2-fy-2020-revenue-of-%24205-million-and-29.4-operating-margin-2019
https://www.nasdaq.com/press-release/abiomed-second-quarter-fiscal-2020-earnings-and-conference-call-notification-2019-10
https://www.nasdaq.com/press-release/abiomed-announces-1000th-patient-treated-with-impella-in-japan-2019-10-07
https://www.nasdaq.com/press-release/highest-court-in-germany-affirms-strength-of-abiomeds-patents-2019-09-23
https://www.nasdaq.com/press-release/lifshitz-miller-llp-announces-investigation-of-abiomed-inc.-adtran-inc.-amtrust
https://www.nasdaq.com/press-release/abiomed-to-highlight-importance-of-optimal-pci-treatment-to-improve-outcomes-for-high
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-15
https://www.nasdaq.com/press-release/rosen-a-top-ranked-law-firm-announces-filing-of-securities-class-action-lawsuit-6
https://www.nasdaq.com/press-release/lead-plaintiff-deadline-alert%3a-faruqi-faruqi-llp-encourages-investors-who-suffered-43
https://www.nasdaq.com/press-release/abmd-shareholder-alert%3a-bernstein-liebhard-llp-announces-that-a-securities-class
https://www.nasdaq.com/press-release/bragar-eagel-squire-p.c.-announces-that-a-class-action-lawsuit-has-been-filed-against
https://www.nasdaq.com/press-release/bronstein-gewirtz-grossman-llc-announces-investigation-of-abiomed-inc.-abmd-2019-08
